{"hands_on_practices": [{"introduction": "A foundational principle in pharmacotherapy is understanding the time course of drug accumulation. Before we can assess a drug's clinical effect or tolerability, we must wait for its concentration to reach a stable level, or steady state. This practice bridges the gap between the theoretical concept of elimination half-life ($t_{1/2}$) and the practical clinical heuristic that steady state is reached in approximately 4 to 5 half-lives, providing a quantitative basis for when to time dose adjustments and evaluate patient response [@problem_id:4741084].", "problem": "A patient with Major Depressive Disorder is initiated on once-daily escitalopram with the intention to maintain a constant daily input and achieve a pharmacokinetic steady state under linear, first-order elimination. Assume a one-compartment model with first-order elimination and that escitalopram exhibits an elimination half-life $t_{1/2} \\approx 27$ hours. Using the fundamental relationship between the elimination rate constant and half-life, and the exponential approach of concentration toward steady state under constant input, derive from first principles why clinicians often use a small multiple of $t_{1/2}$ to estimate the time window to approach steady state. Then, compute the earliest and latest expected times to reach practical steady state (defined operationally by clinicians as the point where further accumulation is minimal) by evaluating the window that corresponds to this commonly used heuristic. Provide these two times as numerical values in days. Round each value to three significant figures and express your answers in days. Finally, justify the clinical implications of this window for timing dose adjustments and assessment of pharmacodynamic effects.", "solution": "The problem asks for a derivation of the clinical heuristic for the time to reach pharmacokinetic steady state, a calculation of this time window for escitalopram, and a justification of its clinical implications. The analysis is based on a one-compartment model with first-order elimination.\n\nFirst, we derive the relationship between time and the fraction of steady state achieved. The rate of change of drug concentration, $C(t)$, in a single compartment model under constant input rate $R_0$ (as in a zero-order infusion) is described by the differential equation:\n$$ \\frac{dC(t)}{dt} = \\frac{R_0}{V_d} - k_{el}C(t) $$\nwhere $V_d$ is the volume of distribution and $k_{el}$ is the first-order elimination rate constant. For a patient starting with no drug in their system, the initial condition is $C(0)=0$. The solution to this first-order linear ordinary differential equation is:\n$$ C(t) = C_{ss}(1 - \\exp(-k_{el}t)) $$\nHere, $C_{ss} = \\frac{R_0}{k_{el}V_d}$ is the drug concentration at steady state ($t \\to \\infty$). Although the patient takes a once-daily dose (a multiple-dosing regimen), the accumulation of the average drug concentration to its steady-state level follows the same exponential time course predicted by this continuous-infusion model. The time to reach this steady-state level is determined solely by the elimination rate constant $k_{el}$.\n\nThe fraction of the steady-state concentration, $f_{ss}$, achieved at time $t$ is the ratio of $C(t)$ to $C_{ss}$:\n$$ f_{ss}(t) = \\frac{C(t)}{C_{ss}} = 1 - \\exp(-k_{el}t) $$\nNext, we must relate $k_{el}$ to the elimination half-life, $t_{1/2}$. The half-life is defined as the time it takes for the drug concentration to decrease by $50\\%$ during the elimination phase. For a first-order process, this relationship is given by:\n$$ \\frac{1}{2} = \\exp(-k_{el}t_{1/2}) $$\nTaking the natural logarithm of both sides yields:\n$$ \\ln\\left(\\frac{1}{2}\\right) = -k_{el}t_{1/2} \\implies -\\ln(2) = -k_{el}t_{1/2} $$\nSolving for $k_{el}$, we find:\n$$ k_{el} = \\frac{\\ln(2)}{t_{1/2}} $$\nSubstituting this expression for $k_{el}$ into the equation for $f_{ss}(t)$:\n$$ f_{ss}(t) = 1 - \\exp\\left(-\\frac{\\ln(2)}{t_{1/2}}t\\right) $$\nTo understand the clinical heuristic, we express time $t$ as a multiple $n$ of half-lives, such that $t = n \\cdot t_{1/2}$.\n$$ f_{ss}(n) = 1 - \\exp\\left(-\\frac{\\ln(2)}{t_{1/2}} \\cdot n \\cdot t_{1/2}\\right) = 1 - \\exp(-n\\ln(2)) $$\nUsing the identity $a\\ln(b) = \\ln(b^a)$ and $\\exp(\\ln(x)) = x$, this simplifies to:\n$$ f_{ss}(n) = 1 - 2^{-n} = 1 - \\left(\\frac{1}{2}\\right)^n $$\nThis fundamental relationship shows that the fraction of steady state achieved depends only on the number of half-lives, $n$, that have passed. Evaluating for integer values of $n$:\n- For $n=1$: $f_{ss} = 1 - (\\frac{1}{2})^1 = 0.50$ (i.e., $50\\%$ of $C_{ss}$)\n- For $n=2$: $f_{ss} = 1 - (\\frac{1}{2})^2 = 0.75$ (i.e., $75\\%$ of $C_{ss}$)\n- For $n=3$: $f_{ss} = 1 - (\\frac{1}{2})^3 = 0.875$ (i.e., $87.5\\%$ of $C_{ss}$)\n- For $n=4$: $f_{ss} = 1 - (\\frac{1}{2})^4 = 0.9375$ (i.e., $\\approx 94\\%$ of $C_{ss}$)\n- For $n=5$: $f_{ss} = 1 - (\\frac{1}{2})^5 = 0.96875$ (i.e., $\\approx 97\\%$ of $C_{ss}$)\nAfter $4$ half-lives, the drug concentration has reached nearly $94\\%$ of its final value. After $5$ half-lives, it reaches $97\\%$. At this stage, the rate of further accumulation is minimal, justifying the clinical definition of having reached a \"practical steady state\". This provides the first-principles basis for the common clinical heuristic that steady state is approached within a window of $4$ to $5$ half-lives.\n\nWe now apply this to escitalopram, with a given half-life of $t_{1/2} \\approx 27$ hours.\nThe earliest expected time corresponds to $n=4$ half-lives:\n$$ t_{early} = 4 \\times t_{1/2} = 4 \\times 27 \\text{ hours} = 108 \\text{ hours} $$\nThe latest expected time corresponds to $n=5$ half-lives:\n$$ t_{late} = 5 \\times t_{1/2} = 5 \\times 27 \\text{ hours} = 135 \\text{ hours} $$\nTo express these times in days, we divide by $24$ hours/day:\n$$ t_{early, \\text{days}} = \\frac{108}{24} = 4.5 $$\n$$ t_{late, \\text{days}} = \\frac{135}{24} = 5.625 $$\nRounding to three significant figures as requested:\n$$ t_{early} \\approx 4.50 \\text{ days} $$\n$$ t_{late} \\approx 5.63 \\text{ days} $$\n\nThe clinical implications of this window from approximately $4.5$ to $5.6$ days are profound:\n1.  **Assessment of Efficacy and Tolerability**: Pharmacodynamic effects, both therapeutic and adverse, are driven by drug concentration. A stable drug concentration (steady state) is a prerequisite for a stable clinical effect. Therefore, clinicians must wait for this period to pass before they can meaningfully assess a patient's response to a specific dose. Evaluating too early would lead to erroneous conclusions because the drug concentration is still increasing.\n2.  **Dose Adjustments**: If a change in dose is required due to lack of efficacy or unacceptable side effects, it should only be considered after steady state has been reached on the current regimen. Modifying a dose before this time makes it impossible to disentangle the effects of the initial dose from the effects of the new, accumulating dose. For escitalopram, this principle supports waiting at least a week before making dose adjustments.\n3.  **Patient Education**: This calculation is crucial for managing patient expectations. A patient starting an antidepressant must understand that drug levels need about a week to build up and stabilize, and that the clinical benefits may take even longer to manifest due to the need for downstream neuroadaptive changes. This knowledge helps improve treatment adherence and reduces patient anxiety about a perceived lack of immediate effect.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n4.50 & 5.63\n\\end{pmatrix}\n}\n$$", "id": "4741084"}, {"introduction": "Just as important as understanding drug accumulation is understanding drug elimination, a concept with critical implications for patient safety. When switching between medications, particularly from an agent with a long half-life like fluoxetine to one with a high potential for dangerous interactions like a monoamine oxidase inhibitor (MAOI), a carefully calculated washout period is non-negotiable. This exercise demonstrates how to apply first-order pharmacokinetic principles to determine the necessary washout duration, translating a theoretical decay process into a life-saving clinical decision to prevent serotonin syndrome [@problem_id:4741031].", "problem": "A patient with recurrent major depressive disorder has been taking fluoxetine daily for more than $8$ weeks. Because fluoxetine has an active metabolite, norfluoxetine, with prolonged elimination, switching to a monoamine oxidase inhibitor (MAOI; monoamine oxidase inhibitor) requires a washout interval long enough for residual norfluoxetine exposure to become clinically negligible. Assume norfluoxetine follows one-compartment, first-order elimination with norfluoxetine half-life $t_{1/2} = 9.3$ days, and that steady-state under daily dosing reflects substantial accumulation because the dosing interval $\\tau = 1$ day is much shorter than the half-life. Let $C_{\\mathrm{ss}}$ denote the steady-state concentration immediately before the next dose during chronic daily dosing, and let $C(t)$ denote the norfluoxetine concentration at time $t$ after the last dose is taken. For safety when initiating an irreversible MAOI, require the residual norfluoxetine concentration to be below a conservative fraction $f = \\frac{1}{16}$ of $C_{\\mathrm{ss}}$ at the time the MAOI is started. Using first principles of first-order pharmacokinetics and accumulation under repeated dosing, derive the minimal washout time $t_{\\mathrm{wash}}$ such that $C(t_{\\mathrm{wash}}) \\le f\\,C_{\\mathrm{ss}}$, and compute its numerical value. Round your final answer to three significant figures and express it in days.", "solution": "The problem asks for the minimum washout time, $t_{\\mathrm{wash}}$, for norfluoxetine, ensuring its concentration drops to a safe level before starting an MAOI. The process is modeled as first-order elimination.\n\nThe elimination of a drug following first-order kinetics is described by the equation:\n$$C(t) = C_0 \\exp(-k_e t)$$\nwhere $C(t)$ is the concentration at time $t$, $C_0$ is the initial concentration, and $k_e$ is the first-order elimination rate constant. The washout begins after the last dose, so we set the initial concentration $C_0$ to the steady-state trough concentration, $C_{\\mathrm{ss}}$. Thus, $C(0) = C_{\\mathrm{ss}}$.\n\nThe elimination rate constant $k_e$ is related to the half-life $t_{1/2}$ by:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}}$$\n\nThe safety condition requires that at time $t_{\\mathrm{wash}}$, the concentration $C(t_{\\mathrm{wash}})$ must be at or below a fraction $f$ of the initial steady-state concentration:\n$$C(t_{\\mathrm{wash}}) \\le f C_{\\mathrm{ss}}$$\nSubstituting the decay equation:\n$$C_{\\mathrm{ss}} \\exp(-k_e t_{\\mathrm{wash}}) \\le f C_{\\mathrm{ss}}$$\nDividing by $C_{\\mathrm{ss}}$ (which is non-zero) and solving for the minimal time by taking the equality:\n$$\\exp(-k_e t_{\\mathrm{wash}}) = f$$\nTaking the natural logarithm of both sides:\n$$-k_e t_{\\mathrm{wash}} = \\ln(f)$$\n$$t_{\\mathrm{wash}} = -\\frac{\\ln(f)}{k_e}$$\nSubstitute the expression for $k_e$:\n$$t_{\\mathrm{wash}} = -\\frac{\\ln(f) \\cdot t_{1/2}}{\\ln(2)}$$\n\nThe problem specifies the safety fraction $f = \\frac{1}{16}$. We can express this as $f = \\left(\\frac{1}{2}\\right)^4$.\nSubstituting this into the equation for $t_{\\mathrm{wash}}$:\n$$t_{\\mathrm{wash}} = -\\frac{\\ln\\left(\\left(\\frac{1}{2}\\right)^4\\right) \\cdot t_{1/2}}{\\ln(2)} = -\\frac{4 \\ln\\left(\\frac{1}{2}\\right) \\cdot t_{1/2}}{\\ln(2)} = -\\frac{4 (-\\ln(2)) \\cdot t_{1/2}}{\\ln(2)}$$\nThis simplifies to:\n$$t_{\\mathrm{wash}} = 4 t_{1/2}$$\nThis result is intuitive: to reduce the concentration to $\\frac{1}{16} = \\left(\\frac{1}{2}\\right)^4$ of its initial value, exactly $4$ half-lives must pass.\n\nUsing the given half-life for norfluoxetine, $t_{1/2} = 9.3$ days:\n$$t_{\\mathrm{wash}} = 4 \\times 9.3 \\text{ days} = 37.2 \\text{ days}$$\nThe result, $37.2$, already has three significant figures. Thus, the minimal washout time required is $37.2$ days.", "answer": "$$\\boxed{37.2}$$", "id": "4741031"}, {"introduction": "Effective pharmacotherapy often requires moving beyond standard dosing to a personalized approach tailored to the individual patient's unique physiology and risk factors. This advanced practice integrates pharmacokinetics (PK) and pharmacodynamics (PD) to rationally determine a maximum safe dose in a complex clinical scenario. By modeling how factors like age, hepatic impairment, and drug interactions alter drug clearance ($CL$) and how comorbidities can increase pharmacodynamic sensitivity, you will learn to quantitatively adjust dosing to balance efficacy with safety, a core skill in modern psychopharmacology [@problem_id:4741071].", "problem": "A patient with a major depressive disorder is being considered for citalopram. You are asked to explain the pharmacotherapy reasoning that connects citalopram concentration to corrected QT interval prolongation and then derive a maximum daily dose in an elderly patient with hepatic impairment, incorporating patient-specific risk factors in a mechanistically justified way.\n\nUse the following fundamental bases:\n\n- At steady state for a one-compartment model with first-order elimination, the average total plasma concentration under multiple dosing is given by $C_{\\text{ss,avg}} = \\dfrac{F \\, D}{CL \\, \\tau}$, where $F$ is oral bioavailability, $D$ is the total daily dose, $CL$ is clearance, and $\\tau$ is the dosing interval.\n- The exposure–response for citalopram’s effect on corrected QT interval (QTc) is assumed to be linear in the total average steady-state concentration: $\\Delta QTc \\propto C_{\\text{ss,avg}}$.\n- The clinically allowed increment in QTc is bounded by a threshold $\\Delta QTc \\leq E_{\\max}$ to mitigate torsades de pointes risk.\n- You may assume $1 \\,\\text{mg}/\\text{L} = 1000 \\,\\text{ng}/\\text{mL}$.\n\nYou are provided calibration data from a thorough QT study in healthy adults:\n\n- At a daily dose $D = 40$ $\\text{mg/day}$ in healthy adults with $CL_{\\text{adult}} = 16$ $\\text{L/h}$, $F = 0.8$, and $\\tau = 24$ $\\text{h}$, the mean QTc increment is $\\Delta QTc = 12.6$ $\\text{ms}$. Use this datum to derive the proportionality constant for the linear exposure–response on the total concentration (denote it $k_{t}$, with units $\\text{ms}\\,/\\,(\\text{ng}/\\text{mL})$).\n\nNow consider a seventy-six-year-old female with moderate hepatic impairment (Child–Pugh class B), mild bradycardia and mild hypokalemia, and concomitant omeprazole therapy (a cytochrome P450 2C19 inhibitor). Incorporate the following scientifically justified modifiers:\n\n- Elderly status reduces clearance multiplicatively by a factor of $0.85$.\n- Moderate hepatic impairment reduces clearance multiplicatively by a factor of $0.70$.\n- Concomitant omeprazole further reduces clearance multiplicatively by a factor of $0.833$.\n- The susceptibility of myocardial repolarization to a given concentration is modestly increased due to bradycardia and hypokalemia; model this as a multiplicative susceptibility factor $s = 1.1$ applied to the exposure–response slope.\n\nAssume the same bioavailability $F = 0.8$ and dosing interval $\\tau = 24$ $\\text{h}$ apply to this patient. For safety, impose an allowed increment threshold of $E_{\\max} = 12$ $\\text{ms}$ (that is, the predicted $\\Delta QTc$ must not exceed $E_{\\max}$).\n\nStarting only from the fundamental bases stated above, derive and compute the maximum daily dose $D_{\\max}$ that keeps the predicted $\\Delta QTc$ at or below $E_{\\max}$ in this patient. Round your final numerical dose to $3$ significant figures and express it in $\\text{mg/day}$.", "solution": "The central task is to determine the maximum daily dose, $D_{\\max}$, of citalopram for a specific elderly patient with multiple risk factors for QTc prolongation. The reasoning connects the administered dose to the resultant plasma concentration, and subsequently, this concentration to the physiological effect on the heart's corrected QT interval (QTc). The solution is a two-step process: first, calibrating the exposure-response model using data from healthy adults, and second, applying this model to the patient, incorporating all specified risk factors.\n\nThe fundamental relationships provided are:\n1.  The average steady-state plasma concentration, $C_{\\text{ss,avg}}$, is given by a one-compartment model:\n    $$C_{\\text{ss,avg}} = \\frac{F \\, D}{CL \\, \\tau}$$\n    where $F$ is oral bioavailability, $D$ is the total daily dose, $CL$ is the total body clearance, and $\\tau$ is the dosing interval.\n\n2.  The change in the QTc interval, $\\Delta QTc$, is linearly proportional to the total average steady-state concentration:\n    $$\\Delta QTc = k_{t} \\, C_{\\text{ss,avg}}$$\n    where $k_{t}$ is the proportionality constant, or the exposure-response slope.\n\n**Step 1: Calibration of the Exposure-Response Model**\n\nWe first determine the value of the proportionality constant $k_{t}$ using the provided calibration data from a study in healthy adults.\n\nGiven data for healthy adults:\n- Dose, $D_{\\text{adult}} = 40 \\, \\text{mg/day}$\n- Bioavailability, $F = 0.8$\n- Clearance, $CL_{\\text{adult}} = 16 \\, \\text{L/h}$\n- Dosing interval, $\\tau = 24 \\, \\text{h}$\n- Mean QTc increment, $\\Delta QTc_{\\text{adult}} = 12.6 \\, \\text{ms}$\n\nFirst, we calculate the average steady-state concentration in these adults. The dose $D$ is given as $40 \\, \\text{mg/day}$, which corresponds to a dose of $40 \\, \\text{mg}$ given over the dosing interval $\\tau = 24 \\, \\text{h} = 1 \\, \\text{day}$.\n$$C_{\\text{ss,avg,adult}} = \\frac{F \\, D_{\\text{adult}}}{CL_{\\text{adult}} \\, \\tau} = \\frac{0.8 \\times 40 \\, \\text{mg}}{16 \\, \\text{L/h} \\times 24 \\, \\text{h}} = \\frac{32}{384} \\, \\frac{\\text{mg}}{\\text{L}} = \\frac{1}{12} \\, \\frac{\\text{mg}}{\\text{L}}$$\nThe problem requires $k_t$ in units of $\\text{ms} / (\\text{ng/mL})$. We must convert the concentration units using the given conversion factor $1 \\, \\text{mg/L} = 1000 \\, \\text{ng/mL}$.\n$$C_{\\text{ss,avg,adult}} = \\frac{1}{12} \\, \\frac{\\text{mg}}{\\text{L}} \\times 1000 \\, \\frac{\\text{ng/mL}}{\\text{mg/L}} = \\frac{1000}{12} \\, \\frac{\\text{ng}}{\\text{mL}} = \\frac{250}{3} \\, \\frac{\\text{ng}}{\\text{mL}}$$\nNow, we can solve for $k_{t}$:\n$$k_{t} = \\frac{\\Delta QTc_{\\text{adult}}}{C_{\\text{ss,avg,adult}}} = \\frac{12.6 \\, \\text{ms}}{(250/3) \\, \\text{ng/mL}} = \\frac{12.6 \\times 3}{250} \\, \\frac{\\text{ms}}{\\text{ng/mL}} = \\frac{37.8}{250} \\, \\frac{\\text{ms}}{\\text{ng/mL}} = 0.1512 \\, \\frac{\\text{ms}}{\\text{ng/mL}}$$\n\n**Step 2: Derivation of the Maximum Dose for the Patient**\n\nNext, we construct the model for the seventy-six-year-old female patient. Her clearance, $CL_{\\text{patient}}$, is reduced from the healthy adult value by several multiplicative factors:\n- Age factor, $f_{\\text{age}} = 0.85$\n- Hepatic impairment factor, $f_{\\text{hepatic}} = 0.70$\n- Omeprazole interaction factor, $f_{\\text{omeprazole}} = 0.833$\n\nThe patient's total clearance is:\n$$CL_{\\text{patient}} = CL_{\\text{adult}} \\times f_{\\text{age}} \\times f_{\\text{hepatic}} \\times f_{\\text{omeprazole}}$$\nThe patient's QTc response is also modified. Her comorbidities (bradycardia, hypokalemia) increase her myocardial susceptibility to QTc-prolonging effects. This is modeled by a multiplicative susceptibility factor, $s = 1.1$, applied to the exposure-response slope.\nThe QTc change for the patient, $\\Delta QTc_{\\text{patient}}$, is therefore:\n$$\\Delta QTc_{\\text{patient}} = s \\, k_{t} \\, C_{\\text{ss,avg,patient}}$$\nwhere\n$$C_{\\text{ss,avg,patient}} = \\frac{F \\, D_{\\text{patient}}}{CL_{\\text{patient}} \\, \\tau}$$\nWe need to find the maximum dose, $D_{\\max}$, that satisfies the safety constraint $\\Delta QTc_{\\text{patient}} \\leq E_{\\max}$, where $E_{\\max} = 12 \\, \\text{ms}$. We find $D_{\\max}$ by setting $\\Delta QTc_{\\text{patient}} = E_{\\max}$.\n$$E_{\\max} = s \\, k_{t} \\, \\left( \\frac{F \\, D_{\\max}}{CL_{\\text{patient}} \\, \\tau} \\right)$$\nSolving for $D_{\\max}$:\n$$D_{\\max} = \\frac{E_{\\max} \\, CL_{\\text{patient}} \\, \\tau}{s \\, k_{t} \\, F}$$\nSubstituting the expression for $CL_{\\text{patient}}$:\n$$D_{\\max} = \\frac{E_{\\max} \\, (CL_{\\text{adult}} \\times f_{\\text{age}} \\times f_{\\text{hepatic}} \\times f_{\\text{omeprazole}}) \\, \\tau}{s \\, k_{t} \\, F}$$\nFor a more elegant derivation, we can express $D_{\\max}$ in terms of the adult reference dose, $D_{\\text{adult}}$. From the calibration step, we know that $D_{\\text{adult}} = \\frac{\\Delta QTc_{\\text{adult}} \\, CL_{\\text{adult}} \\, \\tau}{k_{t} \\, F}$. Rearranging this gives $\\frac{CL_{\\text{adult}} \\, \\tau}{k_{t} \\, F} = \\frac{D_{\\text{adult}}}{\\Delta QTc_{\\text{adult}}}$.\nWe can substitute this into our expression for $D_{\\max}$:\n$$D_{\\max} = E_{\\max} \\times \\frac{1}{s} \\times (f_{\\text{age}} \\times f_{\\text{hepatic}} \\times f_{\\text{omeprazole}}) \\times \\left( \\frac{CL_{\\text{adult}} \\, \\tau}{k_{t} \\, F} \\right)$$\n$$D_{\\max} = \\frac{E_{\\max}}{\\Delta QTc_{\\text{adult}}} \\times \\frac{1}{s} \\times (f_{\\text{age}} \\times f_{\\text{hepatic}} \\times f_{\\text{omeprazole}}) \\times D_{\\text{adult}}$$\nThis final form shows that the maximum dose for the patient is the reference adult dose, scaled by a ratio of acceptable QTc effects, the inverse of the susceptibility factor, and the product of all clearance reduction factors.\n\n**Step 3: Numerical Calculation**\n\nWe now substitute the numerical values into the derived expression for $D_{\\max}$:\n- $E_{\\max} = 12 \\, \\text{ms}$\n- $\\Delta QTc_{\\text{adult}} = 12.6 \\, \\text{ms}$\n- $s = 1.1$\n- $f_{\\text{age}} = 0.85$\n- $f_{\\text{hepatic}} = 0.70$\n- $f_{\\text{omeprazole}} = 0.833$\n- $D_{\\text{adult}} = 40 \\, \\text{mg/day}$\n\n$$D_{\\max} = \\left( \\frac{12}{12.6} \\right) \\times \\left( \\frac{1}{1.1} \\right) \\times (0.85 \\times 0.70 \\times 0.833) \\times 40 \\, \\text{mg/day}$$\nFirst, calculate the product of the clearance factors:\n$$f_{\\text{age}} \\times f_{\\text{hepatic}} \\times f_{\\text{omeprazole}} = 0.85 \\times 0.70 \\times 0.833 = 0.495635$$\nNow, compute $D_{\\max}$:\n$$D_{\\max} = \\left( \\frac{12}{12.6} \\right) \\times \\left( \\frac{1}{1.1} \\right) \\times 0.495635 \\times 40 \\, \\text{mg/day}$$\n$$D_{\\max} \\approx 0.95238 \\times 0.90909 \\times 0.495635 \\times 40 \\, \\text{mg/day}$$\n$$D_{\\max} \\approx 17.1628 \\, \\text{mg/day}$$\nRounding the final answer to $3$ significant figures as requested, we get $17.2 \\, \\text{mg/day}$. This result suggests a maximum daily dose of approximately $20 \\, \\text{mg}$ is often recommended for such patients, aligning with this quantitative derivation.", "answer": "$$\\boxed{17.2}$$", "id": "4741071"}]}